Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang : Efusi pleura merupakan salah satu komplikasi dari kanker atau penyakit keganasan yang sering terjadi. Efusi pleura maligna termasuk dalam 15% sampai dengan 35% dari seluruh kejadian efusi pleura dan angka kejadiannya mencapai 660 orang per 1 juta populasi secara global. Beberapa model prediksi telah dievaluasi untuk memprediksi mortalitas pada pasien efusi pleura maligna. Skor PROMISE merupakan sebuah model prediksi mortalitas 3 bulan pada pasien dengan efusi pleura maligna. Tujuan : Penelitian ini bertujuan untuk mengevaluasi performa kalibrasi dan diskriminasi skor Clinical PROMISE dalam memprediksi mortalitas tiga bulan pada pasien efusi pleura maligna. Metode : Penelitian ini menggunakan metode kohort retrospektif yang melibatkan pasien efusi pleura maligna yang terdaftar tahun 2015-2022 di Rumah Sakit Umum Pusat Nasional Dokter Cipto Mangunkusumo. Dilakukan penilaian mortalitas tiga bulan. Data terkumpul dianalisis dengan uji Hosmer-Lemeshow goodness-of-fit untuk mengetahui performa kalibrasi dan pembuatan kurva Receiver Operating Curve (ROC) untuk mengetahui performa diskriminasi skor Clinical PROMISE terhadap luaran mortalitas tiga bulan. Hasil : Diperoleh 120 subjek yang disertakan dalam penelitian dengan proporsi mortalitas 60,8%. Mayoritas subjek adalah perempuan (73,3%), rerata usia 55 tahun, kanker tipe lain (78,3%). Skor Clinical PROMISE memiliki performa kalibrasi yang baik (p = 0,230, koefisien korelasi r = 0,945). Performa diskriminasi skor Clinical PROMISE baik dengan AUC 0,849 (IK95% 0,776 –0,922). Kesimpulan : Performa kalibrasi dan diskriminasi skor Clinical PROMISE dalam memprediksi mortalitas tiga bulan pada pasien efusi pleura maligna adalah baik.

---

Background : Pleural effusion is a frequent complication of cancer or malignant disease. Malignant pleural effusion accounts for 15% to 35% of all pleural effusion cases and the incidence rate reaches 660 people per 1 million population globally. Several prediction models have been evaluated to predict mortality in malignant pleural effusion patients. The PROMISE score is a prediction model for 3-month mortality in patients with malignant pleural effusion. Aim : This study aims to evaluate the calibration and discrimination performance of the Clinical PROMISE score to predict three-month mortality in malignant pleural effusion patients. Methods : This study used a retrospective cohort method involving malignant pleural effusion patients registered in 2015-2022 at Dokter Cipto Mangunkusumo National Central General Hospital. A three-month mortality assessment was carried out. The collected data was analyzed using the Hosmer-Lemeshow goodness-of-fit test to determine the calibration performance and creation of a Receiver Operating Curve (ROC) curve to determine the discrimination performance of the Clinical PROMISE score on three-month mortality outcomes. Results : There were 120 included in the study with the proportion of mortality as high as 60.8%. The majority of subjects were women (73.3%), mean age 55 years, other types of cancer (78.3%). The Clinical PROMISE score had good calibration performance (p = 0.230, coefficient of correlation r = 0.945). The discrimination performance of the Clinical PROMISE score was good with an AUC of 0.849 (95% CI 0.776 –0.922). Conclusion : The calibration and discrimination performance of Clinical PROMISE score ini prediction 3-month mortality of malignant pleural effusion is good."

"Serous (peritoneal, pleural and pericardial) effusions are a frequently encountered clinical finding in everyday medical practice and one of the most common specimen types submitted for cytological evaluation. The correct diagnosis of effusions is critical for patient management, as well as for prognostication and yet many clinicians find diagnosis and treatment of cancer cells in effusions very challenging.Featuring multiple microscopic illustrations of all diagnostic entities and ancillary techniques (immunhistochemistry and molecular methods), this book provides a comprehensive, authoritative guide to all aspects of serous effusions, including etiology, morphology and ancillary diagnostic methods, as well as data related to therapeutic approaches and prognostication. Section one covers diagnosis for benign and malignant effusions including the etiological reasons for the accumulation of effusions that provides the reader with the full spectrum of differential diagnoses at this anatomic site. Section Two discusses biology, therapy and prognosis highlighting clinical approaches that may be of value to patients and the movement towards personalized medicine and targeted therapy."